# Re-examination Study For Varivax (V210-059 AM2)

> **NCT01062061** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 754 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** VARIVAX™

## Key facts

- **NCT ID:** NCT01062061
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 754 (ACTUAL)
- **Last updated:** 2015-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062061, "Re-examination Study For Varivax (V210-059 AM2)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT01062061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*